Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema
Regeneron’s anti-VEGF Eylea has long dominated its market, but competitors are looking to dethrone the king — particularly Novartis’ latecomer Beovu. Hampered by prior safety concerns, Novartis has set Eylea directly in its sights with a pair of non-inferiority studies for Beovu that could help it get over the line in macular edema.
Novartis’ Beovu matched Regeneron’s anti-VEGF Eylea a year after treatment at improving diabetic macular edema patients’ eyesight in the drug’s second head-to-head swing at the market leader, Novartis said Tuesday.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
